Who are Replimune Group, Inc.'s main suppliers?

Replimune Group, Inc. (REPL) key suppliers include: Hercules Capital, Inc., Hercules Capital, Inc., ROCHE, Genelux Corporation. View the full supplier network at chainsifter.com/chain/REPL.

Who are Replimune Group, Inc.'s major customers?

Replimune Group, Inc. (REPL) key customers include: Bristol-Myers Squibb Company, Bristol-Myers Squibb Company, Bristol-Myers Squibb Co, Bristol-Myers Squibb Co, Genelux Corporation and 7 more. View the full customer network at chainsifter.com/chain/REPL.

What sector is Replimune Group, Inc. in?

Replimune Group, Inc. (REPL) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Replimune Group, Inc. Supplier List (REPL): 4 Verified Suppliers

4Suppliers

12Customers

3Debt Items

20Related Chains

Source-Backed Evidence Depth

Replimune Group, Inc. (REPL) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

20Total relationships

2Distinct source URLs

7High confidence

0.763Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Replimune Group, Inc. Suppliers

Ticker	Name	Confidence	Evidence
HTGC	Hercules Capital, Inc.	90%	Reciprocal relationship from HTGC graph: Reciprocal relationship from REPL graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from REPL graph: the Company, Hercules, and the Lend…
HTGC	Hercules Capital, Inc.	90%	the Company, Hercules, and the Lenders agreed to amend the Loan and Security Agreement
ROCHE	ROCHE	90%	The ongoing study in HCC is being developed in combination with atezolizumab and bevacizumab under a supply and clinical collaboration agreement with Roche.
GNLX	Genelux Corporation	72%	Reciprocal relationship from GNLX graph: nd equipped our own manufacturing facility in order to secure supplies for clinical trials and commercial launch. The facility includes laboratories, producti…

Replimune Group, Inc. Customers

Ticker	Name	Confidence	Evidence
BMY	Bristol-Myers Squibb Company	72%	Reciprocal relationship from BMY graph: Reciprocal relationship from REPL graph: Reciprocal relationship from BMY graph: Reciprocal relationship from REPL graph: the Company's common stock, and 333,1…
BMY	Bristol-Myers Squibb Company	72%	the Company's common stock, and 333,130 and 148,190 restricted stock units under employment inducement grants. Stock option valuation The fair value of stock option grants is estimated using the Blac…
BMYMP	Bristol-Myers Squibb Co	72%	the Company's common stock, and 333,130 and 148,190 restricted stock units under employment inducement grants. Stock option valuation The fair value of stock option grants is estimated using the Blac…
BMYMP	Bristol-Myers Squibb Co	72%	Reciprocal relationship from BMYMP graph: Reciprocal relationship from REPL graph: the Company's common stock, and 333,130 and 148,190 restricted stock units under employment inducement grants. Stock…
GNLX	Genelux Corporation	72%	Reciprocal relationship from GNLX graph: nd equipped our own manufacturing facility in order to secure supplies for clinical trials and commercial launch. The facility includes laboratories, producti…
HTGC	Hercules Capital, Inc.	72%	rkets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. A weak or declining economy or political disruptio…
HTGC	Hercules Capital, Inc.	72%	Reciprocal relationship from HTGC graph: Reciprocal relationship from REPL graph: rkets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate m…
INTS	Intensity Therapeutics, Inc.	72%	Reciprocal relationship from INTS graph: n when they do not submit claims directly to government payors if they are deemed to “cause” the submission of false or fraudulent claims. The government may …
IRELAND-LIMITED	IRELAND-LIMITED	62%	(“Replimune US”); Replimune Securities Corporation; and Replimune (Ireland) Limited. The Company is subject to risks and uncertainties common to companies in the biotechnology industry, including, bu…
LEERINK-PARTNERS-LLC	LEERINK-PARTNERS-LLC	62%	complex and continue to evolve. There can be no assurance that our security efforts and measures will be effective or that attempted security breaches or disruptions would not be successful or damagi…
REPLIMUNE-SECURITIES-CORPORATION	REPLIMUNE-SECURITIES-CORPORATION	62%	(“Replimune US”); Replimune Securities Corporation; and Replimune (Ireland) Limited. The Company is subject to risks and uncertainties common to companies in the biotechnology industry, including, bu…
REPLIMUNE-UK-REPLIMUNE-US-REPLIMUNE-SECURITIES-C	REPLIMUNE-UK-REPLIMUNE-US-REPLIMUNE-SECURITIES-C	62%	(“Replimune US”); Replimune Securities Corporation; and Replimune (Ireland) Limited. The Company is subject to risks and uncertainties common to companies in the biotechnology industry, including, bu…

Replimune Group, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
REPL-DEBT-12132	Warrants outstanding: 5284238	90%	xbrl warrant detail from xbrl 2022-03-31.
REPL-DEBT-12133	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2019-03-31.
REPL-DEBT	Debt stack $84.1M	90%	Market cache reports total debt of $84.1M.

Replimune Group, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Replimune Group, Inc..

Replimune Group, Inc. Ownership

Holder	Name	Confidence	Evidence
REPL-OWNER-BAKER-BROS-ADVISORS-LP	BAKER BROS. ADVISORS LP	90%	13F overlay lists BAKER BROS. ADVISORS LP as top holder; 187 tracked holders.

Replimune Group, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
CMPS	COMPASS Pathways plc	100.00	2
DRTS	Alpha Tau Medical Ltd.	100.00	2
ALEC	Alector, Inc.	100.00	2
ATON	AlphaTON Capital Corp	100.00	2
GNLX	Genelux Corporation	100.00	1	['customer', 'supplier']
BCYC	Bicycle Therapeutics plc	100.00	2
BEAM	Beam Therapeutics Inc.	100.00	2
CPMV	Mosaic ImmunoEngineering, Inc.	100.00	2
TLSA	Tiziana Life Sciences Ltd	100.00	2
EMMA	Emmaus Life Sciences, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
CLLS	Cellectis S.A.	100.00	2
IRON	Disc Medicine, Inc.	100.00	2
ALT	Altimmune, Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
DYN	Dyne Therapeutics, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2
HOWL	Werewolf Therapeutics, Inc.	100.00	2

Replimune Group, Inc. Supply Chain